Guardant Health Inc
GH: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|>& | LOCK|KN^ | LOCK|^l^c%$R |
Guardant Health Earnings: Results and Guidance in Line With Expectations; Shares Fairly Valued
Guardant Health's fourth-quarter results and guidance were both in line with our expectations. We maintain our $47 fair value estimate, and we currently view shares as fairly valued. We think the company has healthy tailwinds going into 2025, including robust double-digit revenue growth, improving gross profit margins, and an eventful calendar that will help shape expectations of the sales trajectories for Shield (colorectal cancer screening) and Reveal (surveillance of cancer survivors).
